JP2013541582A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541582A5
JP2013541582A5 JP2013537287A JP2013537287A JP2013541582A5 JP 2013541582 A5 JP2013541582 A5 JP 2013541582A5 JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013541582 A5 JP2013541582 A5 JP 2013541582A5
Authority
JP
Japan
Prior art keywords
adhd
pharmaceutically acceptable
lurasidone
acid addition
acceptable acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541582A (ja
JP5855670B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013537287A priority Critical patent/JP5855670B2/ja
Priority claimed from JP2013537287A external-priority patent/JP5855670B2/ja
Publication of JP2013541582A publication Critical patent/JP2013541582A/ja
Publication of JP2013541582A5 publication Critical patent/JP2013541582A5/ja
Application granted granted Critical
Publication of JP5855670B2 publication Critical patent/JP5855670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537287A 2010-11-08 2011-05-24 精神疾患の治療方法 Active JP5855670B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013537287A JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41108110P 2010-11-08 2010-11-08
US61/411,081 2010-11-08
JP2011033453 2011-02-18
JP2011033453 2011-02-18
JP2013537287A JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法
PCT/JP2011/062314 WO2012063513A1 (en) 2010-11-08 2011-05-24 Method of treatment for mental disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015240067A Division JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2013541582A JP2013541582A (ja) 2013-11-14
JP2013541582A5 true JP2013541582A5 (enExample) 2014-07-10
JP5855670B2 JP5855670B2 (ja) 2016-02-09

Family

ID=46020227

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537287A Active JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法
JP2015240067A Active JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015240067A Active JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Country Status (6)

Country Link
US (5) US8258139B2 (enExample)
EP (1) EP2638038A4 (enExample)
JP (2) JP5855670B2 (enExample)
CN (1) CN103180315A (enExample)
CA (1) CA2814828C (enExample)
WO (1) WO2012063513A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565776A (zh) * 2012-07-25 2014-02-12 天津市汉康医药生物技术有限公司 一种稳定的鲁拉西酮胶囊药物组合物
US9732065B2 (en) 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
US10272080B2 (en) 2013-09-13 2019-04-30 Florida State University Research Foundation, Inc. Selective dopamine D4 receptor agonists for treatment of working memory deficits
JP6594351B2 (ja) 2014-06-16 2019-10-23 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DK36291D0 (da) 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
IL110011A (en) 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
WO1996014297A1 (en) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
JP3775823B2 (ja) 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
US5688798A (en) 1995-10-10 1997-11-18 Hoffmann-La Roche Inc. Pyrimidine compounds
US6228875B1 (en) 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
JP2000281576A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd イミド誘導体を含有するプロテオグリカン生成促進剤
AR027134A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
US20020082283A1 (en) 2000-09-14 2002-06-27 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
DK1327440T5 (da) 2000-09-22 2009-09-07 Dainippon Sumitomo Pharma Co Orale pr parater med gunstige nedbrydningsegenskaber
EP1353675A2 (en) 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
BR0210391A (pt) 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
JP4568463B2 (ja) 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンa発現抑制動物神経細胞及び非ヒトモデル動物
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
CA2475839A1 (en) 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1535616B1 (en) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
WO2004113333A1 (ja) 2003-06-23 2004-12-29 Dainippon Sumitomo Pharma Co., Ltd. 老人性痴呆症治療剤
WO2005080976A1 (ja) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
US7122683B2 (en) * 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
CN101198331B (zh) * 2005-06-13 2012-05-02 大日本住友制药株式会社 增溶化制剂
TW200812993A (en) 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
CN101663308A (zh) 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
MY153868A (en) 2007-04-04 2015-03-30 Merck Sharp & Dohme Therapeutic agents
JP2008135074A (ja) 2008-02-25 2008-06-12 Fujitsu Ltd 情報公開方法および情報公開装置

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
JP2012255026A5 (enExample)
JP2010529118A5 (enExample)
JP2014528474A5 (enExample)
JP2013525444A5 (enExample)
JP2013509429A5 (enExample)
JP2014521735A5 (enExample)
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
JP2015524444A5 (enExample)
JP2016517888A5 (enExample)
JP2013518107A5 (enExample)
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
JP2013541583A5 (enExample)
JP2013519675A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
CY1119597T1 (el) Συνθεσεις και μεθοδοι για υπερκεραση αντοχης σε τραμαδολη
JP2014512355A5 (enExample)
JP2012504560A5 (enExample)
JP2015516419A5 (enExample)
JP2013541582A5 (enExample)